Avalo Therapeutics (traded under the ticker symbol AVTX) operates within the Healthcare sector and more specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical firm, its core business operations are dedicated to discovering, developing, and commercializing targeted therapeutics and monoclonal antibodies designed to address immune-mediated inflammatory diseases and severe autoimmune conditions with significant remaining unmet medical needs.